Even though G6PD deficiency provides clinical protection against Plasmodium spp., G6PD-deficient patients are susceptible to haemolytic anaemia when exposed to active and toxic metabolites of primaquine (PQ) and tafenoquine (TQ) [7–9]. This evidence concerns the gene G6PD and hyperinsulinemic hypoglycemia, familial, 4.